Quick Overview: Ariela Noy, MD, discusses considerations for selecting A review of a phase 3 trial on cabozantinib as well as the use of regorafenib and ramucirumab as seen in the RESORCE and ... The panelists, Johanna Bendell, MD; George P. Kim, MD; and Caio Rocha Lima, MD, explain clinical trial results evaluating ...
Second Line Therapy In Advanced - Detailed Overview & Context
Ariela Noy, MD, discusses considerations for selecting A review of a phase 3 trial on cabozantinib as well as the use of regorafenib and ramucirumab as seen in the RESORCE and ... The panelists, Johanna Bendell, MD; George P. Kim, MD; and Caio Rocha Lima, MD, explain clinical trial results evaluating ... Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, describes a retrospective analysis on the efficacy of Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the joint meeting of the EAU and ... Lung cancer expert Dr Rebecca Heist highlights the role of antibody-drug conjugates in the
Robert Alter, MD, of John Theurer Cancer Center, defines Dr. Ramanathan discusses ongoing clinical trials in both front-line and Urothelial carcinomas affect parts of the urinary system. The prognosis for Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase II KEYNOTE-224 trial ... This video was supported through a medical grant from Intercept. In this episode, Patrick Horne, NP from the University of Florida, ... Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, discusses
A key opinion leader discusses the decision factors for switching from first-line to Ariela Noy, MD, reviews clinical data supporting the use of ibrutinib as
